- Home
- STOK
as 01-17-2025 4:00pm EST
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 721.4M | IPO Year: | 2019 |
| Target Price: | $21.83 | AVG Volume (30 days): | 933.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.09 - $17.58 | Next Earning Date: | 11-05-2024 |
| Revenue: | $16,742,999 | Revenue Growth: | 81.08% |
| Revenue Growth (this year): | 105.42% | Revenue Growth (next year): | -17.10% |
Stock Insider Trading Activity of Stoke Therapeutics Inc. (STOK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Skorpios Trust | STOK | 10% Owner | Dec 23 '24 | Sell | $11.50 | 2,000,000 | $23,000,000.00 | 6,906,181 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 9 '24 | Sell | $12.99 | 2,586 | $33,595.50 | 44,746 | |
| Kaye Edward M. MD | STOK | CEO | Dec 9 '24 | Sell | $12.99 | 6,786 | $88,158.28 | 61,885 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Dec 9 '24 | Sell | $13.34 | 13,666 | $185,978.06 | 23,028 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 6 '24 | Sell | $12.78 | 13,945 | $178,182.24 | 44,746 | |
| Kaye Edward M. MD | STOK | CEO | Dec 6 '24 | Sell | $12.78 | 6,170 | $78,837.18 | 61,885 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Dec 6 '24 | Sell | $12.78 | 9,696 | $123,890.64 | 23,028 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 1 '24 | Sell | $12.07 | 10,000 | $120,698.00 | 44,746 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Nov 1 '24 | Sell | $12.68 | 10,000 | $126,803.00 | 44,746 |
Latest Stoke Therapeutics Inc. News
STOK Breaking Stock News: Dive into STOK Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BioPharma Dive
11 days ago
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results
MT Newswires
12 days ago
Stoke Therapeutics Reports Alignment With Regulators for Dravet Syndrome Trial
MT Newswires
12 days ago
Wedbush Raises Stoke Therapeutics' Price Target to $19 From $17, Keeps Outperform Rating
Business Wire
12 days ago
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
Business Wire
12 days ago
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
Zacks
24 days ago
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
Zacks
a month ago
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Compare STOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STOK Stoke Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.